Trials / Completed
CompletedNCT02483208
Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate
Single Dose, Open-label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the pharmacokinetics of BAY81-8973 and Advate after intravenous administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY81-8973 | BAY81-8973 infusion to analyze pharmacokinetics |
| DRUG | Advate | Advate infusion to analyze pharmacokinetics. |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2015-07-01
- Completion
- 2015-12-01
- First posted
- 2015-06-26
- Last updated
- 2016-02-17
Locations
1 site across 1 country: Bulgaria
Source: ClinicalTrials.gov record NCT02483208. Inclusion in this directory is not an endorsement.